financetom
Business
financetom
/
Business
/
Osisko Development Was Down 1.4% In US Premarket Trade Even After Narrowing Full-Year 2023 Net Loss YOY
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Osisko Development Was Down 1.4% In US Premarket Trade Even After Narrowing Full-Year 2023 Net Loss YOY
Apr 1, 2024 3:40 AM

06:30 AM EDT, 04/01/2024 (MT Newswires) -- Osisko Development Corp. ( ODV ) was as of near 4am ET down 1.4% in Us premarket trade after over the holiday weekend reporting a full-year 2023 net loss of $181.9 million, or a loss of $2.21 per basic and diluted share, narrowing from a loss of $192.5 million, or a loss of $3.02 per share, in 2022.

Full-year 2023 revenues amounted to $31.6 million, down from $64.0 million in 2022.

The company sold 10,743 ounces of gold in 2023, composed of 4,959 ounces from the Trixie test mine within the Tintic project, 3,272 ounces from the Cariboo gold project and 2,512 ounces from the San Antonio gold project.

Among Q4 highlights, 2,090 ounces of gold were sold by the company from operating activities in the fourth quarter. It reported $6.9 million in revenues ($31.6 million in 2023) and $6.4 million in cost of sales ($32.3 million in 2023) generated from operating activities in the fourth quarter.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Neuronetics Q3 revenue misses estimates
Neuronetics Q3 revenue misses estimates
Nov 4, 2025
Overview * Neuronetics Q3 2025 revenue rose 101% yr/yr but missed analyst expectations * U.S. Greenbrook clinic revenue grew 25% on an adjusted pro forma basis * CEO Keith J. Sullivan to retire in June 2026, search for successor underway Outlook * Company expects Q4 2025 revenue between $40 mln and $43 mln * Neuronetics ( STIM ) revises 2025...
Sotera Health beats Q3 estimates, raises FY profit guidance
Sotera Health beats Q3 estimates, raises FY profit guidance
Nov 4, 2025
Overview * Sotera Health ( SHC ) Q3 revenue rose 9.1% to $311 mln, beating analyst expectations * Adjusted EPS for Q3 increased to $0.26, surpassing analyst estimates * Adjusted EBITDA for Q3 rose 12.2% to $164 mln, exceeding expectations Outlook * Sotera Health ( SHC ) raises 2025 Adjusted EBITDA growth range to 6.75%-7.75% * Company reaffirms 2025 net...
InspireMD Q3 revenue beats estimates on commercial launch of CGuard Prime
InspireMD Q3 revenue beats estimates on commercial launch of CGuard Prime
Nov 4, 2025
Overview * InspireMD ( NSPR ) Q3 revenue grows 39% yr/yr, beating analyst expectations * Net income for Q3 beats analyst estimates despite larger net loss * Company attributes revenue growth to U.S. launch and international market penetration Outlook * InspireMD ( NSPR ) highlights strong demand for its CGuard Prime globally * Company emphasizes strategic focus on U.S. commercial...
Royalty Pharma Acquires Royalty Interest in Alnylam’s AMVUTTRA for $310 Million from Blackstone Life Sciences
Royalty Pharma Acquires Royalty Interest in Alnylam’s AMVUTTRA for $310 Million from Blackstone Life Sciences
Nov 4, 2025
NEW YORK and CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc ( RPRX ) today announced that it has acquired a royalty interest in Alnylam’s AMVUTTRA from funds managed by Blackstone Life Sciences (“Blackstone”) for $310 million. The royalty interest being sold stems from Blackstone’s 2020 financing collaboration with Alnylam, in which Blackstone invested to support AMVUTTRA’s...
Copyright 2023-2026 - www.financetom.com All Rights Reserved